| Synonyms: | |
| Status: | Phase 3 |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| UNII: | 4JR41A10VP |
| InChI Key | HZQDCMWJEBCWBR-UUOKFMHZSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C9H13N3O6 |
| Molecular Weight | 259.22 |
| AlogP | -2.7 |
| Hydrogen Bond Acceptor | 8.0 |
| Hydrogen Bond Donor | 5.0 |
| Number of Rotational Bond | 3.0 |
| Polar Surface Area | 151.06 |
| Molecular species | NEUTRAL |
| Aromatic Rings | 1.0 |
| Heavy Atoms | 18.0 |
| Action | Mechanism of Action | Reference |
|---|---|---|
| INHIBITOR | GMP synthase [glutamine-hydrolyzing] inhibitor | PubMed |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Transporter
Electrochemical transporter
SLC superfamily of solute carriers
SLC21/SLCO family of organic anion transporting polypeptides
|
- | - | - | - | 100 |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Arthritis, Rheumatoid | 3 | D001172 | ClinicalTrials |
| Nephrotic Syndrome | 3 | D009404 | ClinicalTrials |
| Lupus Nephritis | 3 | D008181 | ClinicalTrials |
| Resources | Reference |
|---|---|
| CAS NUMBER | 50924-49-7 |
| ChEBI | 31858 |
| ChEMBL | CHEMBL245019 |
| DrugBank | DB12617 |
| DrugCentral | 3363 |
| EPA CompTox | DTXSID8045777 |
| FDA SRS | 4JR41A10VP |
| Human Metabolome Database | HMDB0041934 |
| PDB | MZR |
| PubChem | 104762 |
| SureChEMBL | SCHEMBL7118 |
| ZINC | ZINC000003812887 |